Business
Vertex Beats Estimates, but a Rival 50 Times Smaller Looms Over Its Cystic Fibrosis Empire
Vertex raised guidance on $3.2B in quarterly CF sales, yet analysts are watching tiny Sionna Therapeutics, whose experimental drug could layer on top of Vertex’s Trikafta.